Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons

Chronic hepatitis C infection is common among patients with human immunodeficiency virus (HIV) infection. In this randomized trial, 133 patients were assigned to receive either peginterferon alfa-2a with ribavirin or interferon alfa-2a with ribavirin. The rate of sustained virologic response was higher in the peginterferon group than in the interferon group (27 percent vs. 12 percent). Coinfection with hepatitis C virus (HCV) is common among persons infected with the human immunodeficiency virus (HIV), with a prevalence ranging from 4 to 92 percent depending on the underlying risk factors. Since the introduction of potent antiretroviral therapy, liver disease due to HCV coinfection has become a major source of mortality among HIV-infected persons. 1 – 3 The progression of liver disease appears to be accelerated in such persons. 4 Treatment regimens based on interferon and ribavirin are recommended for chronic hepatitis C but pose special concerns in persons coinfected with HIV, particularly those who are receiving antiretroviral therapy. Common side effects . . .